Drug Safety Update: May 2020

MHRA Drug Safety Update

May 2020

Coronavirus (COVID-19): new dedicated Yellow Card reporting site for medicines and medical devices

Reporting to the new site will enable the MHRA to rapidly identify new and emerging side effects and medical device incidents in COVID-19 treatment, including side effects for medicines taken by patients to manage long-term or pre-existing conditions.

Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19)

Guidance has been published to support initiation of valproate in female patients and for annual review and pregnancy testing during the coronavirus pandemic.

Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)

Guidance has been published about thalidomide, lenalidomide, and pomalidomide and the use of remote consultations and home pregnancy testing for patients taking them during COVID-19.

Letters and drug alerts sent to healthcare professionals in April 2020

A summary of letters and drug alerts recently sent to healthcare professionals.

It's easy to report

Report a suspected adverse drug reaction online
or download the Yellow Card app

REPORT ONLINE

If you would like to share this with a friend or colleague, hit the Forward button or send them this link to view the email in a browser.

Unsubscribe or change your email address at any time on your subscriber preferences page.

If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

All other enquiries can be directed to email.support@mhra.gov.uk.

This is an automatically generated email. Please do not reply directly to this notification.
This service is provided to you at no charge by the Medicines and Healthcare products Regulatory Agency.